Literature DB >> 25665761

A detailed description and assessment of outcomes of patients with hospital recorded QTc prolongation.

Zachary Laksman1, Bogdan Momciu2, You Won Seong2, Patricia Burrows2, Susan Conacher2, Jaimie Manlucu2, Peter Leong-Sit2, Lorne J Gula2, Allan C Skanes2, Raymond Yee2, George J Klein2, Andrew D Krahn3.   

Abstract

Corrected QT (QTc) interval prolongation has been shown to be an independent predictor of mortality in many clinical settings and is a common finding in hospitalized patients. The causes and outcomes of patients with extreme QTc interval prolongation during a hospital admission are poorly described. The aim of this study was to prospectively identify patients with automated readings of QTc intervals >550 ms at 1 academic tertiary hospital. One hundred seventy-two patients with dramatic QTc interval prolongation (574 ± 53 ms) were identified (mean age 67.6 ± 15.1 years, 48% women). Most patients had underlying heart disease (60%), predominantly ischemic cardiomyopathy (43%). At lease 1 credible and presumed reversible cause associated with QTc interval prolongation was identified in 98% of patients. The most common culprits were QTc interval-prolonging medications, which were deemed most responsible in 48% of patients, with 25% of these patients taking ≥2 offending drugs. Two patients were diagnosed with congenital long-QT syndrome. Patients with electrocardiograms available before and after hospital admission demonstrated significantly lower preadmission and postdischarge QTc intervals compared with the QTc intervals recorded in the hospital. In conclusion, in-hospital mortality was high in the study population (29%), with only 4% of patients experiencing arrhythmic deaths, all of which were attributed to secondary causes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25665761     DOI: 10.1016/j.amjcard.2015.01.016

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

2.  Prevalence and Risk Factors of Drug-Associated Corrected QT Prolongation in Elderly Hospitalized Patients: Results of a Retrospective Analysis of Data Obtained Over 6 Months.

Authors:  Ophélie Maison; Blandine de la Gastine; Laurent Dayot; Sylvain Goutelle
Journal:  Drugs Aging       Date:  2017-07       Impact factor: 3.923

Review 3.  Risk assessment tools for QT prolonging pharmacotherapy in older adults: a systematic review.

Authors:  Simone Skullbacka; Marja Airaksinen; Juha Puustinen; Terhi Toivo
Journal:  Eur J Clin Pharmacol       Date:  2022-02-14       Impact factor: 2.953

4.  QT prolongation predicts short-term mortality independent of comorbidity.

Authors:  Charlotte Gibbs; Jacob Thalamus; Doris Tove Kristoffersen; Martin Veel Svendsen; Øystein L Holla; Kristian Heldal; Kristina H Haugaa; Jan Hysing
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

5.  Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients.

Authors:  Simone Schächtele; Thomas Tümena; Karl-Günter Gaßmann; Martin F Fromm; Renke Maas
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

6.  Impact of Drug Induced Long QT Syndrome: A Systematic Review.

Authors:  Karuppiah Arunachalam; Seetha Lakshmanan; Abhishek Maan; Narendra Kumar; Paari Dominic
Journal:  J Clin Med Res       Date:  2018-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.